Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines

European Journal of Medicinal Chemistry

Volumn 45, Issue 11, 2010, Pages 5022-5030

  Zoidis, Grigoris ^a   Kolocouris, Nicolas ^a   Kelly, John M ^b   Prathalingam, S Radhika ^b   Naesens, Lieve ^c   De Clercq, Erik ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Adamantane aminoalcohols and diamines; Anti influenza A virus agents; H3N2; NMR; Rimantadine; Trypanocidal activity

Indexed keywords

1 [3 (DIMETHYLAMINO)PROPYL] TRICYCLO[3.3.1.1]DECAN 2 OL; 1 PHENYL TRICYCLO[3.3.1.1]DECAN 2 AMINE; 2 (2 AMINOETHYL)TRICYCLO[3.3.1.1]DECAN 2 OL; 2 AMINO N,N DIMETHYL TRICYCLO[3.3.1.1]DECANE 1 PROPANAMINE; 2 AMINOMETHYL 2 HYDROXYADAMANTANE; 2 HYDROXY TRICYCLO[3.3.1.1]DECANE 2 ACETONITRILE; 4 (2 AMINOETHYL)TRICYCLO[4.3.1.0]DECAN 4 OL; 4 [3 (DIMETHYLAMINO)PROPYLO] 4 TRICYCLO[4.3.1.0]DECANOL; 4 TRICYCLO[4.3.1.0]DECANAMIME; ALCOHOL DERIVATIVE; AMANTADINE; AMINO ACID; HYDROXYL GROUP; N METHYL 2 (2 PYRIDINYL) TRICYCLO[3.3.1.1]DECAN 2 AMINE; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; INFLUENZA VIRUS A; NONHUMAN; TRYPANOSOMA; TRYPANOSOMA BRUCEI;

ADAMANTANE; ALCOHOLS; AMINES; ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; INFLUENZA A VIRUS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; SPECTROPHOTOMETRY, INFRARED; TRYPANOSOMA BRUCEI BRUCEI;

EID: 77957840486     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.08.009     Document Type: Article

References (61)

1. J.K. Taubenberger, A.H. Reid, R.M. Lourens, R. Wang, G. Jin, and T.G. Fanning Nature 437 2005 889 893
2. R.J. Webby, and R.G. Webster Science 302 2003 1519 1522
3. C.J. Russell, and R.G. Webster Cell 123 2005 368 371
4. R.G. Webster, R.J. Webby, E. Hoffmann, J. Rodenberg, M. Kumar, H.-J. Chu, P. Seiler, S. Krauss, and T. Songserm Virology 351 2006 303 311
5. A.N. Abdel-Ghafar, T. Chotpitayasunondh, Z. Gao, F.G. Hayden, D.H. Nguyen, M.D. de Jong, A. Naghdaliyev, J.S. Peiris, N. Shindo, S. Soeroso, and T.M. Uyeki N. Eng. J. Med. 358 2008 261 273
6. World Health Organization (WHO) (2009).
7. R.B. Belshe N. Engl. J. Med. 353 2005 2209 2211
8. E. De Clercq, and J. Neyts Trends Pharmacol. Sci. 28 2007 280 285
9. T.M. Tumpey, A. Garcva-Sastre, A. Mikulasova, J.K. Taubenberger, D.E. Swayne, P. Palese, and C.F. Basler Proc. Natl. Acad. Sci. U.S.A. 99 2002 13849 13854
10. N.A. Ilyushina, N.V. Bovin, R.G. Webster, and E.A. Govorkova Antiviral Res. 70 2006 121 131
11. A.J. Hay, A.J. Wolstenholme, J.J. Skehel, and M.H. Smith EMBO J. 4 1985 3021 3024
12. A.J. Hay Semin. Virol. 3 1992 21 30
13. L.H. Pinto, L.J. Holsinger, and R.A. Lamb Cell 69 1992 517 528
14. In Burger's Medicinal Chemistry, fifth ed.; Wolff, M.E., John Wiley & Sons: New York; vol. 4, pp 590-591.
15. N. Kolocouris, G.B. Foscolos, A. Kolocouris, P. Marakos, N. Pouli, G. Fytas, S. Ikeda, and E. De Clercq J. Med. Chem. 37 1994 2896 2902
16. N. Kolocouris, A. Kolocouris, G.B. Foscolos, G. Fytas, J. Neyts, E. Padalko, J. Balzarini, R. Snoeck, A. Graciela, and E. De Clercq J. Med. Chem. 39 1996 3307 3318
17. G. Zoidis, N. Kolocouris, G.B. Foscolos, A. Kolocouris, G. Fytas, P. Karayannis, E. Padalko, J. Neyts, and E. De Clercq Antiviral Chem. Chemother. 14 2003 153 164
18. I. Papanastasiou, A. Tsotinis, N. Kolocouris, S.R. Prathalingam, and J.M. Kelly J. Med. Chem. 51 2008 1496 1500
19. N. Kolocouris, G. Zoidis, G.B. Foscolos, G. Fytas, R.S. Prathalingham, J.M. Kelly, L. Naesens, and E. De Clercq Bioorg. Med. Chem. Lett. 17 2007 4358 4362
20. G. Zoidis, A. Tsotinis, N. Kolocouris, J.M. Kelly, R.S. Prathalingham, L. Naesens, and E. De Clercq Org. Biomol. Chem. 6 2008 3177 3185
21. G. Zoidis, N. Kolocouris, L. Naesens, and E. De Clercq Bioorg. Med. Chem. 17 2009 1534 1541
22. G. Zoidis, D. Benaki, V. Myrianthopoulos, L. Naesens, E. De Clercq, E. Mikros, and N. Kolocouris Tetrahedron Lett. 50 2009 2671 2675
23. E. De Clercq Nat. Rev. Drug Disc. 5 2006 1015 1025
24. A. Kolocouris, P. Spearpoint, S.R. Martin, A.J. Hay, M. López-Querol, F.X. Sureda, E. Padalko, J. Neyts, and E. De Clercq Bioorg. Med. Chem. Lett. 18 2008 6156 6160
25. Recently an X-ray structure of M2TM and M2TM-amantadine complex was published from the DeGrado's group:
26. A.L. Stouffer, R. Acharya, D. Salom, A.S. Levine, L. Di Costanzo, C.S. Soto, V. Tereshko, V. Nanda, S. Stayrook, and W. DeGrado Nature 451 2008 596 599 The first work on the amantadine location inside the M2 protein pore was a neutron diffraction study:
27. K.C. Duff, P.J. Gilchrist, A.M. Saxena, and J.P. Bradshaw Virology 202 1994 287 293 Elegant solid-state NMR studies on this system have been carried out by N. Cross lab:
28. J. Hu, T. Asbury, S. Achuthan, C. Li, R. Bertram, J.R. Quine, R. Fu, and T.A. Cross Biophys. J. 92 2007 4335 4343 For molecular dynamics studies of the M2TM-amantadine or rimantadine complex see:
29. M.S.P. Sansom, and I.D. Kerr Protein Eng. 6 1993 65 74
30. M. Yi, T.A. Cross, and H.-X. Zhou J. Phys. Chem. B 112 2008 7977 7979
31. P. Intharathep, C. Laohpongspaisan, T. Rungrotmongkol, A. Loisruangsin, M. Malaisree, P. Decha, O. Aruksakunwong, K. Chuenpennit, N. Kaiyawet, P. Sompornpisut, S. Pianwanit, and S. Hannongbua J. Mol. Graph. Model. 27 2009 921 929
32. C. Wang, K. Takeuchi, L.W. Pinto, and R.A. Lamb J. Virol. 67 1993 5585 5594
33. I.V. Chizhmakov, F.M. Geraghty, D.C. Ogden, A. Hayhurst, M. Antoniou, and A.J. Hay J. Physiol. 494 1996 329 336
34. L. Pinto, and R.A. Lamb J. Biol. Chem. 281 2006 8997 9000
35. L. Pinto, and R.A. Lamb FEBS Lett. 560 2004 1 2
36. W.B. Fischer, and M.S.P. Sansom Biochim. Biophys. Acta 1561 2002 27 45
37. See the articles in FEBS Lett. 552 2003 1
38. S. Grambas, and A.J. Hay Virology 190 1992 11 18
39. World Health Report, 2004, Statistical Annex Table 2.
40. P.G.E. Kennedy J. Clin. Invest. 113 2004 496 504
41. S.L. Croft, M.P. Barrett, and J.A. Urbina Trends Parasitol. 21 2005 508 512
42. W.E. Gutteridge Brit. Med. Bull. 41 1985 162 168
43. F. Doua, and F.B. Yapo Acta Trop. 54 1993 163 168
44. P.G.E. Kennedy Int. J. Parasitol. 36 2006 505 512
45. J.M. Kelly, M.A. Miles, and A.C. Skinner Antimicrob. Agents Chemother. 43 1999 985 987
46. J.M. Kelly, G. Quack, and M.A. Miles Antimicrob. Agents Chemother. 45 2001 1360 1366
47. J.L.M.A. Schlatmann, J.G. Korsloot, and J. Schut Tetrahedron 26 1970 949 954
48. M.Yu. Skomorokhov, M.V. Leonova, A.K. Shiryaev, and Yu. N. Klimochkin Russ. J. Org. Chem. 39 2003 1360 1361
49. Z. Majersky, and Z. Hamesrak Org. Synth. 50 1988 958 962
50. N. Kolocouris, G. Zoidis, and C. Fytas Synlett 7 2007 1063 1066
51. D. Setaki, D. Tataridis, G. Stamatiou, A. Kolocouris, G.B. Foscolos, G. Fytas, N. Kolocouris, E. Padalko, J. Neyts, and E. De Clercq Bioorg. Chem. 34 2006 248 273
52. C.D. Jones, M. Kaselj, R.N. Salvatore, and W.J. le Noble J. Org. Chem. 63 1998 2758 2760
53. Y.M. Shafran, V.A. Bakulev, and V.S. Mokrushin Russ. Chem. Rev. 58 1989 148 162
54. N.A. Hassan, E. Bayer, and J.C. Jochims J. Chem. Soc., Perkin Trans. 1 1998 3747 3757
55. D. Tataridis, G. Fytas, A. Kolocouris, C. Fytas, N. Kolocouris, G.B. Foscolos, E. Padalko, J. Neyts, and E. De Clercq Bioorg. Med. Chem. Lett. 17 2007 692 696
56. E. Vanderlinden, F. Goktas, Z. Cesur, M. Froeyen, M.L. Reed, C.J. Russell, N. Cesur, and L. Naesens J. Virol. 2010 Feb 24 (Epub ahead of print)
57. L. Naesens, E. Vanderlinden, E. Roth, J. Jeko, G. Andrei, R. Snoeck, C. Pannecouque, E. Illyés, G. Batta, P. Herczegh, and F. Sztaricskai Antiviral Res. 82 2009 89 94
58. S.R. Wilkinson, and J.M. Kelly Expert Rev. Mol. Med. 11 2009 e31
59. S.R. Wilkinson, M.C. Taylor, D. Horn, J.M. Kelly, and I. Cheeseman Proc. Natl. Acad. Sci. USA 105 2008 5022 5027
60. O. Yun, G. Priotto, J. Tong, L. Flevaud, and F. Chappuis PLoS Negl. Trop. Dis. 4 2010 e720
61. S.R. Wilkinson, R. Prathalingam, M.C. Taylor, A. Ahmed, D. Horn, and J.M. Kelly Free Radic. Biol. Med. 40 2006 198 209